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The human cathelicidin anti-microbial protein,
hCAP18 is a component of the innate immune system
and has broad anti-microbial activity conferred by its
C-terminal fragment LL-37. hCAP18 is constitutively
produced in leukocytes and is induced in barrier organs
upon in£ammation and infection.We demonstrate here
a novel role for this peptide in re-epithelialization of
skin wounds. We show that high levels of hCAP18 are
produced in skin in vivo upon wounding. The highest
hCAP18 levels are attained at 48 h post-injury, declining
to pre-injury levels upon wound closure. hCAP18 is de-
tected in the in£ammatory in¢ltrate and in the epithe-
lium migrating over the wound bed. In chronic ulcers,
however, hCAP18 levels are low and immunoreactivity
for hCAP18/LL-37 is absent in ulcer edge epithelium.
Using a nonin£ammatory ex vivo wound healing
model, composed of organ-cultured human skin, we
show that hCAP18 is strongly expressed in healing skin
epithelium, and that treatment with antibodies raised
and a⁄nity puri¢ed against LL-37, inhibits re-epithel-
ialization in a concentration-dependent manner. Im-
munoreactivity for the proliferation marker Ki67 is
absent in the epithelium of such inhibited wounds,
suggesting that LL-37 may play a part in epithelial cell
proliferation. Thus, we suggest that, in addition to
being an anti-microbial peptide, LL-37 also plays a part
in wound closure and that its reduction in chronic
wounds impairs re-epithelialization and may contri-
bute to their failure to heal. Key words: cationic peptide/
keratinocyte/leg ulcer/proliferation/wound healing. J Invest
Dermatol 120:379 ^389, 2003
A
nti-microbial peptides are e¡ector molecules of
the innate immune system that serve to protect the
integrity of the host against potentially harmful
microorganisms.They are conserved through evolu-
tion and are widespread in nature ranging from
plants to mammals, with several hundreds having been character-
ized (Ganz and Lehrer, 1999; Lehrer and Ganz, 1999). In humans,
only a handful have been identi¢ed so far; among which the de-
fensins and the human cationic anti-microbial peptide hCAP18
have been implicated in epithelial defense (Selsted et al, 1983;
Lehrer et al, 1993; Gallo et al, 1994; Harder et al, 1997; Bals
et al, 1998). hCAP18 belongs to the cathelicidin gene family, which
is comprised of more than 20 members in di¡erent species, and
is believed to be the sole cathelicidin protein in humans
(Gudmundsson et al, 1996; Larrick et al, 1996). The holoprotein
consist of an N-terminal part, cathelin, which is conserved
through species and a C-terminal fragment, LL-37, which confers
anti-microbial activity against both gram-positive and gram-ne-
gative bacteria (Agerberth et al, 1995; Gudmundsson et al, 1996).
Cathelin was originally isolated from pig leukocytes and was
proposed to act as an inhibitor of cysteine proteinases (Ritonja
et al, 1989); however, so far no de¢nitive biologic function has
been proven for human cathelin. Activation of hCAP18 requires
proteolytic cleavage, which releases the C-terminus, i.e., LL-37
(Gudmundsson et al, 1996). Serine proteinase 3 was recently
shown to be responsible for extracellular cleavage of hCAP18
(Srensen et al, 2001). LL-37 is thought to function extracellularly
and there is no evidence for intracellular cleavage of the propep-
tide. hCAP18 is synthesized in the bone marrow and stored in
mature neutrophils (Srensen et al, 1997a) and is present in sub-
populations of lymphocytes and monocytes (Agerberth et al,
2000). hCAP18 is also expressed in skin and other epithelia,
where it is upregulated in association with in£ammation, infec-
tion, and injury (Frohm et al, 1997; Goldman et al, 1997; Frohm
Nilsson et al, 1999; Dorschner et al, 2001), consistent with a role
in barrier defense. Additional support for a direct role in skin
anti-microbial defense was recently demonstrated by an enhanced
susceptibility to necrotizing skin infections in mice de¢cient for
the murine cathelicidin protein, CRAMP (Nizet et al, 2001). In-
terestingly, these mice also exhibited insu⁄cient and delayed
wound closure compatible with the notion that cathelicidins
may have multiple roles in barrier defense and repair.
Epithelia constitute the primary barrier between host and the
potentially harmful environment, and therefore the protection of
this interface is vital. Epithelial injury immediately sets in motion
a series of tightly orchestrated events with the purpose of
promptly reinstating the integrity of this barrier. Urgent wound
closure has evolved in higher organisms, diverging from the
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time-consuming process of complete regeneration of tissue seen
in lower species. Impaired wound healing and chronic ulcers con-
stitute a major clinical burden and, regardless of the underlying
cause, such ulcers are characterized by chronic in£ammation
(Herrick et al, 1992; Phillips et al, 1994). This persistent in£amma-
tion creates an environment with elevated levels of cytokines and
proteases. Additionally, there is an imbalance in proteolytic en-
zymes and their endogenous inhibitors (Trengove et al, 1999), all
of which is thought to impair wound healing. Despite consider-
able advances in knowledge about the biology of normal wound
repair, however, our understanding of this fundamental process is
still insu⁄cient and has led to little therapeutic progress in
wound care.
Wound extracts contain anti-microbial substances, including
both LL-37, and various defensins (Frohm et al, 1996). Here we
demonstrate that the human anti-microbial peptide hCAP18 is
upregulated in skin epithelium as a normal response to injury,
which is consistent with and con¢rm recent data from Dorschner
et al (2001). In chronic nonhealing ulcers, however, only low le-
vels of hCAP18 are found and immunoreactive protein is lacking
in wound edge epithelium.We further show that hCAP18 is in-
duced during re-epithelialization of organ-cultured skin wounds,
and that re-epithelialization is inhibited by antibodies against LL-
37 in a concentration-dependent manner. These ¢ndings suggest
that LL-37 plays a crucial part in wound closure.
MATERIALS AND METHODS
Tissue samples The study was approved by the Regional Committee of
Ethics in Stockholm and all samples were used with informed consent.
Patients (n¼ 9) with chronic (46 mo duration) leg ulcers due to venous
insu⁄ciency were recruited at the Department of Dermatology,
Karolinska Hospital, Stockholm (Table I). Individuals with a history of
diabetes mellitus, arterial insu⁄ciency or chronic in£ammatory disease
were excluded. Patients with signs of eczema in the ulcer margin, clinical
signs of infection or undergoing systemic or topical antibiotic treatment at
the time for biopsy were also excluded. Patients included were all treated
with inert local dressings and standard compression bandaging. Punch
biopsies (4 mm) obtained from the wound margin, including 50% of the
epithelialized area, were snap frozen.
For the studies of normal wound healing in vivo, ¢ve surgical wounds
were made with a 3 mm biopsy punch in the abdominal region of
healthy volunteers (n¼ 3), and the wound area was covered with sterile
surgical ¢lm, Tegaderms (3M Health Care, St Paul, MN). The wounds
were subsequently excised with a 6 mm biopsy punch and snap frozen.
These surgical wounds represented the sequential phases of normal
wound healing at 5 min, 12 h, 2 d, 7 d, and 14 d postwounding (Table I).
For the ex vivowound healing model (Kratz et al, 1994), human skin was
obtained from routine abdominal or breast reduction surgery. Under sterile
conditions, full-thickness wounds were made, on the epidermal side, with
a 3 mm biopsy punch. These ex vivo wounds were excised with a 6 mm
biopsy punch and subsequently transferred to 24-well plates and covered
with 2 ml of medium. Such wounds reproducibly re-epithelialize within
4^7 d (Kratz et al, 1994; Inoue et al, 1995; Kratz, 1998). Medium, Dulbecco’s
modi¢ed Eagle’s medium (Gibco BRL, Life Technologies, Scotland)
containing 10% fetal bovine serum and antibiotics (PEST¼penicillin 50
U per liter and streptomycin 50 mg per ml), was changed every third
day. Wounds were harvested at di¡erent time-points, by 2, 4, and 7 d
postwounding and snap frozen. In total, the experiment was repeated four
times, two times for in situ hybridization and immunohistochemistry and
two times for treatment with LL-37 anti-serum. Four di¡erent donors were
used and triplicate wounds were made for each condition in every
experiment. In each experiment, only skin from a single donor was
used.
Table I. Clinical data
Sex/Age (yr) Wound area (cm2) Wound duration (mo) Bacterial culturea
Normal skin
1 F 52 ^ ^ ^
2 ^ ^ ^ ^
3 ^ ^ ^ ^
Surgical wounds in vivo
1 F 29 ^ ^ ^
2 F 63 ^ ^ ^
3 F 52 ^ ^ ^
Chronic ulcers
1 M 40 4 7 ^
2 F 84 26 16 Staphylococcus aureus
Enterococcus species
Mixed gram negative £ora
3 F 52 ^ 36 Staphylococcus aureus
4 F 82 10 6 Staphylococcus aureus
Betaheamolytic group A streptococci
Xanthomonas Maltophilia
5 M 54 9 36 Staphylococcus aureus
Enterobacter cloacae
6 M 88 ^ 9 Staphylococcus aureus
Enterococcus species
Mixed gram negative £ora
7 F 96 ^ 7 Staphylococcus aureus
Mixed gram negative £ora
8 M 61 30 36 Staphylococcus aureus
Enterococcus species
Mixed gram negative £ora
9 F 84 12 21 Staphylococcus aureus
Proteus mirabilis
Experimental wounds ex vivo
1 F 31 ^ ^ ^
2 F 33 ^ ^ ^
3 F 21 ^ ^ ^
4 F 61 ^ ^ ^
aResults of bacterial culture showing colonizing bacteria in leg ulcers without clinical signs of infection.
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All biopsies from the ex vivo wound healing model were serially
completely sectioned. Sections representing maximal re-epithelialization
in the center of the wounds were selected for evaluation.
Preparation of RNA probes A 435 bp hCAP18 length cDNA
(Cowland et al, 1995) was subcloned in Bluescript KS 11 and was used
after linearization with BamHI and EcoRI as a template for in vitro
transcription to generate 35S-labeled anti-sense and sense probes. After
transcription, the RNA probes were ultra¢ltered (Micron 100; Amicon
Inc., Beverly, MA) before hybridization. The speci¢city of this probe has
previously been demonstrated (Frohm Nilsson et al, 1999).
In situ hybridization In situ hybridization was performed as described
(St*hle-B,ckdahl et al, 1992). Brie£y, frozen 6^7 mm thick sections were
hybridized overnight with 2.5106 cpm of 35S-labeled RNA probes at
501C. After hybridization, slides were washed under stringent conditions
including incubation with 50 mg of RNase A (Sigma, St Louis, MO) per
ml for 30 min at 371C and were then processed for autoradiography for
4^5 wk.
Figure1. Expression of hCAP18 in acute surgical in vivowounds during re-epithelialization. (a) At 5 min there was prominent immunoreactivity
for hCAP18 in the basal layer of the epidermis. Arrow indicates the wound edge. (b) After 12 h, intense immunoreactivity was found throughout the wound
edge and in the wound bed in¢ltrate and exudate. (c) By 2 d, strong immunoreactivity for hCAP18 was detected in the epithelial front migrating over the
wound bed (boxed area) and in the wound bed. (d) At 7 d, when re-epithelialization was complete, weak immunoreactivity was found in the basal layer of
epidermis. Focal hCAP18 immunostaining remained in scattered dermal cells. (e) At day 14 single immunoreactive dermal cells remained and in the basal
epidermal layer only weak staining for hCAP18 was detected, comparable with that of normal unwounded skin. (f) Immunoabsorption using cathelin
peptide at 106 M completely abolished the hCAP18 immunoreactivity detected by 7 d. (g) Normal skin with hCAP18 immunoreactivity in the basal cell
layer. Photomicrographs show results obtained with the hCAP18 antibody at 1 : 2000 dilution. Scale bars: (a,b,g) 50 mm; (c^f) 100 mm.
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LL-37 antibody LL-37 peptide (amino acid sequence: H-Leu-Leu-Gly-
Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-
Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-
OH) was synthesized (EuroDiagnostica AB, Malm ,˛ Sweden) according to
Fmoc-strategy using solid phase synthesis (Fields and Noble, 1990) and
puri¢ed by high-performance liquid chromatography to a purity of 98%.
Biologic activity of the peptide was con¢rmed in an anti-bacterial assay
(Frohm et al, 1996). The peptide was used for immunization of three
rabbits according to a standard protocol (AgriSera, V,nn,s, Sweden).
Polyclonal anti-serum was a⁄nity puri¢ed using synthetic LL-37 peptide
and the puri¢ed anti-serum was assessed with enzyme-linked
immunosorbent assay. IgG concentration of the immune serum was
diluted to 0.5 mg per ml. Pre-immune serum was collected from each
rabbit and the IgG concentration was 2 mg per ml.
Immunohistochemistry All biopsies were snap frozen and handled
identically. Samples from both acute and chronic wounds were included
in the same experiments. In short, 6^7 mm thick cryostat sections were
incubated with polyclonal antibody, raised in rabbits against recombinant
hCAP18 and a⁄nity puri¢ed with recombinant cathelin peptide at
dilutions 1 : 1000 and 1 : 2000 (Srensen et al, 1997b) and with polyclonal
LL-37 antibody at dilutions 1 : 1000 and 1 : 2000. All sections were stained
in parallel with both antibodies according to the indirect peroxidase
method using a Vectastain kit (Vector Laboratories, Burlingame, CA) and
following the manufacturer’s instructions. Sections were counterstained
with Mayer’s hematoxylin solution. All experiments were repeated
minimum three times to ensure reproducibility. As controls, serial tissue
sections were processed in parallel without adding primary antibody and
using preimmune rabbit IgG (DAKO, Glostrup, Denmark) as the primary
antibody. For assessment of proliferation in the organ-cultured wound
model, sections representing the di¡erent culture conditions and time-
points were stained with mouse monoclonal Ki67 anti-serum (DAKO) at
1 : 25 dilution as described above.
Immunoabsorption of hCAP18 To ascertain further the speci¢city of
the immunostaining, we performed immunoabsorption adding the anti-
hCAP18 antibody, diluted 1 : 1000, to the recombinant cathelin peptide at
106 M, 108 M, and 1010 M. The mixture was preincubated at þ 41C
overnight and then centrifuged 10,600 g (10,000 r.p.m., 5 min) prior to
immunohistochemical analyses as described above. In parallel, control
sections were processed identically, except that no peptide was added to
absorb the antibody.
Protein extraction Frozen biopsies (22^69 mg) from healthy volunteers
(n¼ 2) and patients (n¼ 3) were cut in 50 mm sections. Cold extraction
bu¡er of 60% aqueous acetonitrile containing 1% tri£uoroacetic acid
(Frohm et al, 1996) was added and samples were eluted on an
Eppendorfshaker (IKA-Vibrax-VXR, Labasco, M˛lndal, Sweden) and
then centrifuged. The supernatants were lyophilized and then diluted in
1000 ml of double distilled H2O. Protein concentrations were measured by
Protein Assay Kit (Bio-Rad Laboratories, Hercules CA) based on the
Bradford method (Bradford, 1976) and samples were diluted to a ¢nal
protein concentration of 1 mg per ml.
Immunoblotting Total protein extracts were separated, adding 30 mg of
each sample to a discontinuous sodium dodecyl sulfate^polyacrylamide
gel electrophoresis using 16.5% Tris-Tricine Ready Gels (Bio-Rad
Laboratories) and then electroblotted on to nitrocellulose ¢lters. After
blocking with 5% skim milk in phosphate-bu¡ered saline for 1 h, the
¢lters were incubated separately overnight with either rabbit polyclonal
hCAP18 antibody a⁄nity puri¢ed against cathelin (1 : 1000) or rabbit
polyclonal antibody (1 : 1000), raised and a⁄nity puri¢ed against synthetic
LL-37 (AgriSera). The ¢lters were then incubated with horseradish-
peroxidase-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Santa
Cruz, CA) followed by development using enhanced chemiluminescence
(Amersham Pharmacia Biotech, Sunnyvale, CA) and exposed with a
CCD camera (Fuji¢lm, Sendai, Japan).
Enzyme-linked immunosorbent assay A sandwich enzyme-linked
immunosorbent assay, using the antibody a⁄nity puri¢ed with cathelin,
previously described was used to quantitate hCAP18 in protein extracts
from patients (n¼ 3) and healthy volunteers (n¼ 2) (Srensen et al, 1997b).
Anti-bacterial assay The classical zone assay was used as described
(Frohm et al, 1996). In short, thin agarose plates, 1 mm, were seeded with
the test bacteria strain Bacillus megaterium. The melted agarose contained
Luria^Bertani broth supplemented with medium E. The test bacteria were
added in the log phase just before pouring the plate. Small wells were
punched in the assay plates and loaded with 3 ml test sample. After
overnight incubation at 301C, the inhibition zones were measured. The
LL-37 peptide was mixed with 10-fold molar excess of LL-37 anti-serum.
The mixture was preincubated for 2 h at room temperature and then
centrifuged 10,600 g (10,000 r.p.m., 5 min) prior to use.
Treatment with LL-37 antibody in the ex vivo wound healing
model Rabbit polyclonal antibody, raised and a⁄nity puri¢ed against
Figure 2. Expression of hCAP18 in migrating epithelial front. (a) High magni¢cation of the boxed area (Fig 1c) visualizes prominent hCAP18 im-
munoreactivity in the epithelial front. (b) Dark-¢eld photomicrograph, of a serial section, demonstrates a matching in situ hybridization signal for hCAP18
mRNA (white grains). (c) Control section hybridized with the sense hCAP18 cRNA probe lacked speci¢c signal hCAP18 mRNA. Immunophotomicro-
graphs show results obtained with the hCAP18 antibody at 1 : 2000 dilution. Scale bar: 10 mm.
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synthetic LL-37 (AgriSera) was used in the experimental wound healing
model described above. LL-37 antibody was added in 2 ml medium per
well (Dulbecco’s modi¢ed Eagle’s mediumþ10% fetal bovine serum and
PEST) to a ¢nal antibody dilution of 1 : 10, 1 : 100, and 1 : 1000. As control
we used the corresponding preimmune serum at a ¢nal IgG concentration
equal to the 1 : 10 dilution of the LL-37 anti-serum. Each experimental
condition was made in triplicates and repeated twice. The media was
changed every third day and LL-37 antibody or preimmune serum was
added as described above. The ex vivo wounds were harvested 2, 4, and 7 d
postwounding. All specimens were snap frozen, sectioned in completion
and mounted on Superfrost Plus slides prior to staining with
hematoxylin^eosin.
RESULTS
hCAP18 is produced in wound edge keratinocytes during
re-epithelialization ex vivo and in vivo but is lacking in
the epithelium of chronic ulcers Upon injury, there was
upregulation of hCAP18 in the epidermis at the wound border
(Fig 1a,b). By 2 d, hCAP18 was clearly expressed in the
migrating front during re-epithelialization both at RNA and
protein levels (Figs 1c and 2a^c). Following wound closure, by
day 7, immunoreactivity for hCAP18 declined in the epidermis
(Fig 1d) and was at 14 d similar to that of intact non-
in£ammatory skin (Fig 1e,g). This pattern of hCAP18 expression
was reproduced in the organ-cultured wounds undergoing re-
epithelialization (Fig 3). Our ¢ndings indicate that regulation of
hCAP18 expression in wound edge keratinocytes does not require
in£ammation.
In contrast to the production of hCAP18 in the epithelial front
of physiologically healing wounds, the epithelium of all nine
chronic ulcers lacked immunoreactivity for hCAP18 (Fig 4). By
in situ hybridization there was prominent signal for hCAP18
mRNA, but no staining for the protein was detected
(Fig 4c,e). Strong immunoreactivity in the wound bed and in
dermal cells served as a positive internal control (Fig 4a,b).
Figure 3. Expression of hCAP18 in the organ-cultured wounds during re-epithelialization. (a) Prominent immunoreactivity was detected in the
epithelial tongue migrating to cover the wound bed. (b) Higher magni¢cation demonstrating that immunoreactivity for hCAP18 was essentially con¢ned
to the basal epithelial cell layer. (c) Dark-¢eld photomicrograph demonstrates a matching signal for hCAP18 mRNA (white grains) in the basal epithelial
layer by in situ hybridization. (d) Control section hybridized with the sense hCAP18 cRNA probe lacked signal for hCAP18 mRNA. (e) Bright-¢eld view of
the boxed area shows hCAP18 mRNA signal as black dots in keratinocytes. (f) High power view demonstrates lack of hCAP18 mRNA in the control
section. Immunophotomicrographs show results obtained with the hCAP18 antibody at 1 : 2000 dilution. Scale bars: (a) 100 mm; (b^d) 10 mm; (e,f) 25 mm.
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Previous studies have shown good correlation between
hCAP18 mRNA and protein levels (Frohm et al, 1997;
Frohm Nilsson et al, 1999; Malm et al, 2000). The results
presented here, however, indicate that hCAP18 protein is not
properly translated, or is rapidly degraded, in the epithelium of
chronic ulcers.
All tissues were immunostained with both hCAP18 and LL-37
anti-sera in parallel. Both anti-sera gave identical results
concerning immunoreactivity in the epithelium. Immuno-
staining in the dermis was slightly more pronounced using the
hCAP18 antibody but there was no qualitative di¡erence
in£uencing interpretation of data. For consistency, all
photomicrographs show results obtained with the hCAP18
antibody.
LL-37 antibody inhibits re-epithelialization in a concentration-
dependent manner in organ-cultured human wounds The
distinct expression of hCAP18 in keratinocytes during
Figure 4. Expression of hCAP18 in a chronic venous leg ulcer. (a) Overview of a chronic ulcer where the left half of the micrograph represents the
epithelium (EP) and the right half represents the wound bed (WB). Prominent immunoreactivity for hCAP18 was detected in the wound bed and in
scattered dermal cells underneath the epithelium. (b) Higher magni¢cation of the boxed area demonstrates the dermoepidermal junction (dotted line) in
detail. Basal keratinocytes essentially lacked immunoreactivity for hCAP18, whereas strong immunostaining was seen in the dermal cells. (c) High magni-
¢cation of the epithelial front (boxed area). Note lack of hCAP18 immunoreactivity in keratinocytes. The dotted line represents the dermoepidermal junc-
tion. Arrow indicates the wound edge. (d) Dark-¢eld photomicrograph of the same tissue as in (c). No signal for hCAP18 mRNA was detected by
hybridization with a control sense probe. (e) Positive signal for hCAP18 mRNAwas detected by hybridization with the anti-sense cRNA probe. Note that
despite the clear signal for hCAP18 mRNA, there was no immunoreactivity for the protein in this area as visualized in the panel above (Fig 4c). Immuno-
photomicrographs show results obtained with the hCAP18 antibody at 1 : 2000 dilution. Scale bars: (a) 100 mm; (b^e) 25 mm.
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re-epithelialization prompted us to investigate whether the
bioactive peptide LL-37 may be directly involved in this process.
The organ-cultured full-thickness wounds reproducibly re-
epithelialize under standard conditions and represent a useful
model for nonin£ammatory wound closure. Adding polyclonal
anti-LL-37 IgG a¡ected re-epithelialization in a concentration-
Figure 5. LL-37 antibody inhibited re-epithelialization in a concentration-dependent manner in the organ cultured full-thickness ex vivo
wound model. (a) Normal control wound completely re-epithelialized at 7 d. Inset shows higher magni¢cation of the epithelium of the right wound
margin comprising two to three cell layers. (b) Preimmune serum, at a ¢nal IgG concentration equal to the 1 : 10 dilution of the LL-37 anti-serum, did not
a¡ect re-epithelialization or the appearance of the epithelium in control wounds at 7 d or the appearance of the epithelium. (c^e) Adding polyclonal anti-LL-
37 IgG a¡ected re-epithelialization in a concentration-dependent manner. (c) The highest concentration of LL-37 anti-serum (1 : 10) severely impaired re-
epithelialization and inhibited wound closure. Higher magni¢cation demonstrates a thin, profoundly a¡ected epithelium. Arrows indicate the epithelial
edges. (d) At 1 : 100 dilution of LL-37 anti-serum, the wound bed was covered with a single layer of keratinocytes with a fragile appearance at day 7. (e) At
1 : 1000 antibody dilution re-epithelialization occurred at a level equal to that of the controls. Scale bars: (a^e) 50 mm; insets 10 mm.
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dependent manner. Normal control wounds (Fig 5a) and
wounds treated with preimmune serum at corresponding IgG
concentrations (Fig 5b) were completely re-epithelialized at 7 d
and comprised of two to three epithelial cell layers. The highest
concentration of LL-37 anti-serum (1 : 10) severely impaired re-
epithelialization and prevented wound closure (Fig 5c). The
lower concentration of LL-37 anti-serum (1 : 100) allowed for
partial wound coverage by 4 d (not shown) and at 7 d the
wound bed was only covered with a thin, fragile layer of
keratinocytes (Fig 5d). At 1 : 1000 antibody dilution re-
epithelialization occurred at a level equal to that of the controls
(Fig 5e). The results from two di¡erent experiments, including
triplicate wounds, were consistent and indicate that LL-37
produced by keratinocytes is required for epithelial wound
closure.
Organ-cultured wounds treated with high concentration of
LL-37 anti-serum lack immunoreactivity for the
proliferation marker Ki67 in the epithelium High number
of immunoreactive keratinocytes were detected in normal
control wounds at day 7 (Fig 6a) but not in the epithelium of
the wound samples treated with LL-37 anti-serum at 1 : 10
dilution inhibiting re-epithelialization (Fig 6b), indicating that
proliferation of the epithelium is impaired in these wounds.
LI-37 antibody blocks the anti-bacterial activity induced by
II-37 peptide Inhibition zone assay demonstrated that LL-37
inhibited growth of Bacillus megaterium in a concentration-
dependent manner. Adding LL-37 anti-serum in a 10-fold molar
excess completely abolished the inhibition of bacterial growth
induced by LL-37 peptide alone (Fig 7).
High levels of hCAP18 are produced during physiologic
wound healing but not in chronic ulcers Upregulation of
hCAP18 occurs as a normal response to skin injury. Maximum
hCAP18 levels with evidence of release of bioactive LL-37
peptide were attained at 12^48 h postwounding and declining to
basal pre-wounding levels at 14 d (Figs 8 and 9). hCAP18 protein
levels in the chronic ulcers were only 10^30% of maximum levels
found in surgical wounds (Fig 8) and LL-37 was barely detected
by immunoblotting (Fig 9). In addition to hCAP18 upregulation
in wound edge keratinocytes, we observed an intense
immunoreactivity in the wound bed in¢ltrate and in the
extracellular interstitium of the surgical wounds (Fig 1b,c). After
re-epithelialization, by day 7 (Fig 1d), hCAP18 immunoreactivity
was less pronounced in the basal epidermal layer with
focal immunoreactivity remaining in scattered dermal cells.
Two weeks after the initial wounding (Fig 1e), only
single immunoreactive dermal cells remained. Epidermis was
still hypertrophic and in basal keratinocytes hCAP18
immunoreactivity was evident and comparable with that of
normal, quiescent skin (Fig 1j). Immunoabsorption using
cathelin peptide at 1010 M decreased hCAP18 immunoreactivity
and at 108 M and 106 M completely abolish it (Fig 1f).
In chronic, nonhealing ulcers hCAP18 immunoreactivity was
most pronounced in the wound bed and essentially lacking in
wound edge epidermis and in the basal epidermal layer (Fig 4a^c).
In addition and analogous to the pattern detected in the surgical
wounds at 7 d, there was prominent immunoreactivity in
scattered dermal cells (Fig 4b). Intact skin from these patients,
obtained from the area proximal to the knee, showed
immunoreactivity for hCAP18 and LL-37 in the basal epithelial
layer analogous to the pattern detected in healthy control skin
(Fig 1g), indicating that there is no generalized defect in
hCAP18 expression in skin from patients with chronic ulcers.
Identi¢cation of the immunoreactive dermal cells in both acute
and chronic wounds indicate that a subset of these cells were
macrophages, by CD68 immunoreactivity in both types of
wounds (data not shown).
Figure 6. Expression of the proliferation marker Ki67 in the organ-cultured wound model. (a) Normal control wound at day 7 demonstrates
multiple Ki67 immunoreactive cells in the basal epithelial layer. (b) Lack of Ki67 immunoreactive cells in the epithelium of the wound sample treated with
LL-37 anti-serum at high concentration, 1 : 10 dilution, which inhibited re-epithelialization. Arrow indicates margin of the fragile epithelium at day 7. Serial
section of the same tissue as shown in Fig 5(c). Scale bar: (a,b) 10 mm.
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DISCUSSION
Anti-microbial peptides such as hCAP18 are now recognized as
being key components of the epithelial defense armament (Hutt-
ner and Bevins, 1999). Only low levels of hCAP18 are present in
nonin£amed intact skin, but upon injury there is strong upregu-
lation in the wounded tissue with protein levels spiking in the
initial phase of wound repair and subsiding upon wound closure.
Our ¢ndings con¢rm recent data that show induction of catheli-
cidin proteins in association with acute wounding in humans and
mice (Dorschner et al, 2001).
In contrast to abundant hCAP18 protein in acute wounds, only
low levels are present in chronic nonhealing ulcers with lack of
immunoreactivity for hCAP18 in the epithelium. In fact, the con-
stitutive hCAP18 expression found in basal keratinocytes in nor-
mal skin, is practically lost in chronic ulcers (Fig 4). Despite lack
of immunoreactive protein, however, there is a prominent signal
for hCAP18 mRNA in the epithelium of chronic ulcers (Fig 4e),
which is an unexpected result. Thus, regulation of hCAP18 pro-
tein production, or post-translational processing, appears to be
disturbed in chronic ulcer keratinocytes. Basal keratinocytes are
critical in cell migration and re-epithelialization and interfering
with their functions is detrimental to healing. In chronic ulcers,
wound edge keratinocytes lose the impetus to change from a sta-
tionary to a migratory and proliferative phenotype. The signals
regulating this process under normal conditions are largely un-
known but it has been shown that the environment in chronic
ulcers is suppressive, as chronic wound £uid inhibits cell prolif-
eration and migration in vitro, whereas acute wound £uid has a
stimulatory e¡ect (Falanga, 1992; Bennett and Schultz, 1993;
Bucalo et al, 1993; Phillips et al, 1998).
What mechanisms may contribute to low levels of hCAP18
and LL-37 in nonhealing ulcers? A fundamental di¡erence be-
tween the microenvironments of acute and chronic ulcers is the
microbial £ora. Current research introduces the novel concept in
the battle between microbes and host, where pathogens develop
strategies to suppress the expression of anti-microbial proteins,
including cathelicidins and defensins (Islam et al, 2001), thereby
facilitating the invasion and infection of the host. Chronic ulcers
are indeed characterized by colonization of a mixture of bacteria
that persist in the wound habitat. Interfering with anti-microbial
e¡ector molecules may provide a clever and e¡ective strategy for
such bacteria simultaneously to evade the host immune defense,
escape death, and prevent closure of their habitat. Highly relevant
to this study are recent ¢ndings demonstrating that bacterial pro-
teinases have the capacity to degrade the anti-microbial peptides
a-defensin (Schmidtchen et al, 2001) and LL-37 (Schmidtchen A,
personal communication). Thus, bacterial spectra in chronic ul-
cers and their abilities to inactivate the endogenous anti-microbial
defense merit further detailed analysis. In this respect, not only
bacteria considered as pathogenic but also strains regarded as
more harmless should be investigated.
Covering of an exposed wound bed with new epithelium re-
presents a critical event in wound repair. In our ex vivo wound
healing model, we studied re-epithelialization in a somewhat re-
stricted sense, namely the simple migration and subsequent pro-
liferation of keratinocytes to form a thin layer of provisional
neoepidermis that does not constitute a complete and functional
barrier. Bearing in mind that this ‘‘naked’’model of epidermal re-
storation does not fully re£ect in vivo complexity, however, our
model does o¡er the potential to dissect mechanisms involved
and the advantage of intact epithelial/stromal architecture, which
is fundamental in re-epithelialization. Our ¢nding that hCAP18
is expressed at mRNA and protein levels in keratinocytes migrat-
ing and proliferating to cover the wound indicates that the ma-
chinery regulating this process is contained within the wound
edge microenvironment and does not require in£ammation.
In order to re-epithelialize reproducibly, the ex vivowounds re-
quire medium containing at least 10% fetal bovine serum (Inoue
et al, 1995; Kratz, 1998). Human serum inhibits anti-microbial and
cytotoxic functions of LL-37, which occur by direct membrane
e¡ect (Johansson et al, 1998), whereas migration of leukocytes in
response to LL-37, a receptor-mediated e¡ect, occurs indepen-
dently of the presence of serum (De et al, 2000). Thus, albeit the
use of fetal and not human serum in our model, it is not likely
that the e¡ect of endogenous LL-37 on wound closure would be
impeded by the present culture conditions.
Our present results on the role of LL-37 in re-epithelialization
are consistent with anti-microbial peptides being multifunctional
Figure 7. LL-37 antibody inhibited the antibacterial activity in-
duced by LL-37 peptide. Inhibition zone assay demonstrating that LL-
37 peptide at (a) 0.05 mg per ml and (b) 0.5 mg per ml inhibited growth
of the test bacterium Bacillus megaterium in a concentration-dependent man-
ner, whereas addition of LL-37 antibody to LL-37 peptide completely
abolishes the anti-bacterial e¡ect. (c) phosphate-bu¡ered saline was used as
a negative control.
Figure 8. hCAP18 protein levels in surgical wounds and in chronic
ulcers. Enzyme-linked immunosorbent assay was performed on protein
extracts from skin biopsies of two surgical wounds (nos 1 and 2 inTable I)
and three chronic venous leg ulcers (nos 7^9 in Table I). The surgical
wounds were obtained at di¡erent time-points from the abdominal region
of healthy volunteers. Peak levels of hCAP18 protein were detected at
2 d postwounding. hCAP18 protein levels in chronic wounds were only
20^30% of the maximum levels in surgical wounds.
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proteins. Thus, LL-37 can block LPS-induced in£ammation
(Nagaoka et al, 2001) and is chemotactic for leukocytes (De et al,
2000). Of potential relevance for this study are the recent ¢ndings
that the porcine cathelicidin protein PR-39 was shown to pro-
mote angiogenesis and induce syndecans in pig wounds (Gallo
et al, 1994; Li et al, 2000). Other data demonstrate that syndecans
are critical in wound healing and mice lacking syndecan-4 genes
show delayed wound healing and impaired angiogenesis (Echter-
meyer et al, 2001). Thus, cathelicidin proteins, including LL-37, are
likely to possess a broad functional repertoire.
In summary, we show that induction of hCAP18 in wound
edge epithelium is a physiologic response to injury that does not
require in£ammation and that blocking its bioactive peptide LL-
37 inhibits wound closure in a concentration-dependent manner.
The mechanisms underlying this inhibition remain to be eluci-
dated, but the lack of Ki67 immunoreactive cells in the epithe-
lium of the suppressed wounds suggests that proliferation of
epithelial cells is a¡ected. Furthermore, we demonstrate that
hCAP18/LL-37 is lacking in chronic ulcer epithelium. These re-
sults indicate that LL-37 is required for re-epithelialization and
suggest that lack of LL-37 in chronic ulcer epithelium may im-
pair epidermal restoration. Further studies are needed to under-
stand fully the role of LL-37 in the re-epithelialization process.
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